A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
about
Adverse effects of biologics: a network meta-analysis and Cochrane overviewNail Psoriasis: A Review of Treatment OptionsTailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesOff-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapyPutting together the psoriasis puzzle: an update on developing targeted therapiesLong-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?Biologic safety in psoriasis: review of long-term safety data.Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patientsAnti-TNFα therapy in the management of psoriasis: experience of a state referral centerEfficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.Psoriasis (chronic plaque)Pathogenic mechanisms shared between psoriasis and cardiovascular diseaseCurrent status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment.How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for PsoriasisThe 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab.Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)Use of biologic agents in combination with other therapies for the treatment of psoriasisBiologics in the management of psoriasis.Update of the management of chronic psoriasis: new approaches and emerging treatment options.The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.Serum levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity.Involvement of TNF-α converting enzyme in the development of psoriasis-like lesions in a mouse model.Current status and future prospects for biologic treatments of psoriasis.Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical TrialsPatient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.TNFalpha blockade in human diseases: an overview of efficacy and safety.A subset of methylated CpG sites differentiate psoriatic from normal skin.The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses.Update on the natural history and systemic treatment of psoriasis.Treatment of severe psoriasis with infliximab.Review and clinical perspectives for the use of infliximab in ulcerative colitis.From conventional to cutting edge: the new era of biologics in treatment of psoriasis.Hepatitis and Lupus-Like Syndrome during Infliximab Therapy for Psoriasis.Infliximab for the treatment of plaque psoriasis.
P2860
Q24234197-C84A1007-AA6F-41C1-A00D-8BB726D6265DQ26753038-CBB43358-E016-42A1-A205-94ABDC3E83E5Q26764867-8C2AA216-0C4D-4FD1-9C9D-557E2350288DQ26827714-FFB2CDBD-E532-4EC0-B75C-2E5C27993124Q27026785-9C2A2F87-FAF9-408A-B271-80663807E0C4Q30574065-6EA9A0CA-201F-4E26-94A1-DEA82E0F5813Q30675199-4AF7670D-C44E-416F-8822-FD6681FEA8A1Q30904076-A99895FB-F73E-4DE4-A580-2369F5AD9AADQ33625546-270B791B-15A7-4C03-90F6-8BD83DA76BABQ33735385-E28ED594-03AB-4A73-B663-97A6BDBD6FBCQ33752359-3615EC52-09A4-447F-9E96-C3702E82DE5AQ33896449-9B6819D7-244E-4369-8632-72A1BEF16571Q33939033-7B3492C9-E85B-4F64-A20E-531F13F387A4Q34010557-70AB469A-E2DC-4E95-AC5B-80771DF86199Q34107573-D3A5B84C-64C6-49D7-B613-DB98D03278FAQ34112840-AB17F6FE-87FC-487B-93E1-20C27D1024EFQ34166896-68215538-6C26-48E5-AD61-B8783082CE2EQ34190076-FBA23CB4-CF24-46A0-8A76-1EC5394492FFQ34385556-082E2436-BD42-4C4D-8D68-61525F1ED7B3Q34393068-87F77B6A-2E27-4E32-910D-41602FA84E73Q34502118-3261402D-AF5E-4B85-8032-A758EED0CE8EQ34516612-5F642E7B-DF54-4947-B839-3D0C44ED440BQ34553755-86081FE6-D714-4910-BEA2-386A070D1953Q34620257-65B0AB24-914F-4D53-91A3-6DEB0F993088Q34620375-71B9A424-691D-45B4-B84C-03B52F528264Q34984568-BFC98556-DF0F-4E88-85F6-426527584F93Q35155926-E607B741-4F64-44EE-A3E8-0B79327939A4Q35407596-42CC549E-5B43-404E-B1A8-2F28151AFF36Q36057909-79C9EA93-7CCA-4F81-89CD-C92274043B91Q36190962-1D6527FA-57B7-4607-A479-A1442E0C24D1Q36368478-B0618D9F-AABF-4D67-96C3-653E8901FA16Q36536861-468D24D0-0763-4954-8BE7-45E23A630CF1Q36600085-40AD6658-F3F8-4F8F-A802-4D50E4CAE315Q37040371-FF87D894-4770-4AB6-B084-17947F8D964EQ37081486-83A56262-E680-49A0-BD53-7B70A36FA972Q37098135-F6DA3483-1688-4AA4-9781-B6865121ADF4Q37114650-50BB9986-4CF5-4555-85E6-E257AE61AAB9Q37131025-864977BD-9D32-473C-8E90-006EEE3A7D0EQ37151335-1A882613-2337-43B5-91AF-ADA5574218E9Q37307554-C6885A61-DD2A-418A-A975-7331DBDE87A4
P2860
A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
A randomized comparison of con ...... te-to-severe plaque psoriasis.
@en
A randomized comparison of con ...... te-to-severe plaque psoriasis.
@nl
type
label
A randomized comparison of con ...... te-to-severe plaque psoriasis.
@en
A randomized comparison of con ...... te-to-severe plaque psoriasis.
@nl
prefLabel
A randomized comparison of con ...... te-to-severe plaque psoriasis.
@en
A randomized comparison of con ...... te-to-severe plaque psoriasis.
@nl
P2093
P1476
A randomized comparison of con ...... ate-to-severe plaque psoriasis
@en
P2093
Alan Menter
Alice B Gottlieb
Cynthia Arnold
Cynthia Guzzo
Gerald D Weinstein
Lisa T Dooley
Robert Evans
P304
P356
10.1016/J.JAAD.2006.07.017
P407
P577
2006-09-06T00:00:00Z